Business
Change negotiations completed at Bioretec
On November 12, 2025, Bioretec announced the start of statutory change negotiations under the Finnish Act on Co-operation within Undertakings, concerning the company's production and marketing operations in Finland. The aim of the negotiations was to streamline and reorganize operations in order to improve the company's competitiveness and profitability.
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Press release 4 December 2025 at 12.00 p.m. EET","length":60,"tagName":"p"},{"type":"text","content":"TAMPERE, Finland, Dec. 4, 2025 /PRNewswire/ -- On November 12, 2025, Bioretec announced the start of statutory change negotiations under the Finnish Act on Co-operation within Undertakings, concerning the company's production and marketing operations in Finland. The aim of the negotiations was to streamline and reorganize operations in order to improve the company's competitiveness and profitability.","length":411,"tagName":"p"},{"type":"text","content":"The negotiations began on November 19, 2025, and were concluded today.","length":70,"tagName":"p"},{"type":"text","content":"At the start of the negotiations, the company estimated that the plans may impact the terms of employment of up to eight employees in Finland. As a result of the negotiations, the employment of two employees will be terminated, and five production employees will be temporarily laid off. In addition, the job description of one employee will undergo significant changes due to the reorganization.","length":396,"tagName":"p"},{"type":"text","content":"The change negotiations are expected to generate annual cost savings of approximately EUR 0.4 million. In total, 15 employees from Bioretec's staff in Finland were included in the scope of the negotiations.","length":210,"tagName":"p"},{"type":"text","content":"As previously announced, Bioretec is currently reviewing its overall commercialization strategy and product development pipeline and will publish an update by the end of 2025.","length":175,"tagName":"p"},{"type":"text","content":"Further enquiriesSarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736","length":73,"tagName":"p"},{"type":"text","content":"About Bioretec","length":14,"tagName":"p"},{"type":"text","content":"Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.","length":431,"tagName":"p"},{"type":"text","content":"Bioretec's Activa product l...